SCHEMBL372255

SCHEMBL372255

O=C(O)/C=C/c1cnc2ccccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 1.00
KDM4E B2RXH2 5/20 0.69
KMT2A Q03164 3/20 0.69
SMN1; SMN2 Q16637 2/20 0.69
PDGFRB P09619 1/20 0.68
PDGFRA P16234 1/20 0.68
ALDH1A1 P00352 5/20 0.57
GAA P10253 4/20 0.57
LMNA P02545 2/20 0.57
MAPT P10636 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
MEN1 O00255 2/20 0.56
NPC1 O15118 1/20 0.56
MGAM O43451 1/20 0.54
RHOA P61586 3/20 0.53
CYP3A4 P08684 1/20 0.52
HDAC3 O15379 2/20 0.52
HDAC4 P56524 2/20 0.52
HDAC1 Q13547 2/20 0.52
HDAC7 Q8WUI4 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL372256 1.00 RAB9A (1.00) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL17461333 1.00 RAB9A (1.00) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
Hydrochloric Acid SCHEMBL6788092 0.98 RAB9A (0.97) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
Hydrochloric Acid SCHEMBL7262691 0.98 RAB9A (0.97) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL6782723 0.89 RAB9A (0.81) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL6421753 0.86 RAB9A (0.75) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL4936531 0.86 RAB9A (0.75) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL6421749 0.86 RAB9A (0.75) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL5717723 0.86 RAB9A (0.75) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB
SCHEMBL8966515 0.86 RAB9A (0.75) RAB9AKDM4EKMT2ASMN1; SMN2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268347-B1 PALLADIUM COMPLEX SALT AND USE THEREOF FOR ADJUSTING PALLADIUM CONCENTRATION OF AN ELECTROLYTIC SOLUTION FOR DEPOSIT OF PALLADIUM OR ONE OF ITS ALLOYS ENGELHARD CLAL SAS (FR) 2005-06-29 EP claimed
EP-1423557-B1 ELECTROLYTIC SOLUTION FOR ELECTROCHEMICAL DEPOSITION OF GOLD AND ITS ALLOYS METALOR TECHNOLOGIES FRANCE S (FR) 2004-12-22 EP claimed
US-6743950-B2 For use in electrical contacts and the connectors used in the field of electronics receive, as a finish, thin layers of electroplated precious metals having brightness, ductility, non-porous and have corrosion resistance METALOR TECHNOLOGIES FRANCE SAS (FR) 2004-06-01 US claimed
US-6743346-B2 AQUEOUS ACIDIC ELECTROLYSIS BATH INCLUDING PALLADIUM COMPOUND, OPTIONAL COMPOUND OF SECONDARY METAL, ETHYLENEDIAMINE AS PALLADIUM COMPLEXING AGENT, AND 3-(3-PYRIDYL)ACRYLIC ACID, 3-(3-QUINOLYL)ACRYLIC ACID OR SALT AS ORGANIC BRIGHTENER METALOR TECHNOLOGIES FRANCE SAS A FRENCH SIMPLIFIED JOINT STOCK COMPANY (FR) 2004-06-01 US claimed
EP-1272691-B1 ELECTROLYTIC SOLUTION FOR ELECTROCHEMICAL DEPOSIT OF PALLADIUM OR ITS ALLOYS METALOR TECHNOLOGIES FRANCE S (FR) 2004-03-17 EP claimed
US-20030183533-A1 Electrolytic solution for electrochemical deposit of palladium or its alloys METALOR TECHNOLOGIES FRANCE SAS A FRENCH SIMPLIFIED JOINT STOCK COMPANY (FR) 2003-10-02 US claimed
US-20030047460-A1 Palladium complex salt and use thereof for adjusting palladium concentration of an electrolytic solution for deposit of palladium or one of its alloys METALOR TECHNOLOGIES FRANCE SAS A FRENCH SIMPLIFIED JOINT STOCK COMPANY (FR) 2003-03-13 US claimed
EP-3538526-B1 CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-04-10 EP disclosed
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed
US-11485725-B2 Derivatives of piperlongumine and uses thereof AURANSA INC. (US) 2022-11-01 US disclosed
US-20210246136-A1 CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-08-12 US disclosed
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2021-07-01 US disclosed
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF AURANSA INC. 2021-07-01 US disclosed
EP-0974584-A1 FUSED RING COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-01-26 EP disclosed
US-5994368-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-11-30 US disclosed
EP-0807105-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-11-19 EP disclosed
WO-1996013485-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-09 WO disclosed
US-4767507-A 3-(3-PYRIDYL) ACRYLIC ACID AND 3-(3-QUINOLYL) ACRYLIC ACID ADDITIVES; CORROSION AND WEAR RESISTANCE ENGELHARD CORPORATION (US) 1988-08-30 US disclosed
US-4216318-A HISTAMINE HZ-ANTAGONISTS, ISOCYTOSINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1980-08-05 US disclosed
US-4154834-A HETEROCYCLIC-(THIO)ALKYLAMINO SUBSTITUTED-4-PYRIMIDONE OR -THIONES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246136-A1 CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS ITGB1, ITGAV, ITGA1 RAB9A 301/4885KDM4E 1994/4885KMT2A 3761/4885
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors ITGB1, ITGB2, ITGA1 RAB9A 329/4885KDM4E 2185/4885KMT2A 3748/4885
US-20210198235-A1 DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF THPO, PIR, PAK6 RAB9A 1941/4885KDM4E 636/4885KMT2A 2507/4885
US-11485725-B2 Derivatives of piperlongumine and uses thereof PIR, THPO, DHPS RAB9A 1731/4885KDM4E 635/4885KMT2A 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.